The Phase 3 TRAILRUNNER-ALZ 1 study, investigating remternetug for Alzheimer's disease, officially reached its primary completion on April 24, 2024. This significant milestone indicates that all participants have completed the primary endpoint assessments for the trial, which enrolled 1667 individuals.
Background
The TRAILRUNNER-ALZ 1 study was designed to gather safety and efficacy information for the investigational drug remternetug (LY3372993). The focus of the trial is on participants diagnosed with early symptomatic Alzheimer's disease (AD), aiming to understand the drug's potential impact in this patient population.
Trial design
The Phase 3 study, identified as NCT05463731, enrolled 1667 participants with Alzheimer's disease. The trial investigated multiple interventions, including remternetug administered intravenously (iv) and subcutaneously (sc), compared against a placebo arm. The primary objective was to collect safety and efficacy data for remternetug in individuals with early symptomatic Alzheimer's disease.
What this means
The primary completion of the TRAILRUNNER-ALZ 1 study signifies that all participants have finished the predefined primary assessments. This milestone indicates that the data collection for the main outcomes of the trial is complete, and the study is now moving towards data analysis and eventual reporting of results. It does not, however, provide any information regarding the efficacy or safety profile of remternetug; those findings will be disclosed once the data has been thoroughly analyzed and published. Clinicians and researchers will await these future disclosures for insights into the potential of remternetug for Alzheimer's disease.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for the study NCT05463731, titled "A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)", was posted on 2024-04-24 on clinicaltrials.gov.